Home>>Signaling Pathways>> Antibody-drug Conjugate/ADC Related>> ADC Linker>>Propargyl-PEG8-NH2

Propargyl-PEG8-NH2

Catalog No.GC66709

Propargyl-PEG8-NH2 (compound 3b) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Propargyl-PEG8-NH2 is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Products are for research use only. Not for human use. We do not sell to patients.

Propargyl-PEG8-NH2 Chemical Structure

Cas No.: 1196732-52-1

Size Price Stock Qty
100mg
$395.00
In stock
250mg
$660.00
In stock
1g
$1,408.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Propargyl-PEG8-NH2 (compound 3b) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs. Propargyl-PEG8-NH2 is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs)[1].

PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker.

[1]. Genady AR, et al. Preparation and Evaluation of Radiolabeled Antibody Recruiting Small Molecules That TargetProstate-Specific Membrane Antigen for Combined Radiotherapy and Immunotherapy. J Med Chem. 2016 Mar 24;59(6):2660-73.

Reviews

Review for Propargyl-PEG8-NH2

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Propargyl-PEG8-NH2

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.